Biocon shares rally nearly 6% after unit receives USFDA nod for cancer drug
Biocon's shares surged following USFDA approval for Jobevne, a biosimilar to Avastin, used in treating various cancers. This marks Biocon's seventh biosimilar approval in the U.S., strengthening its oncology portfolio. With bevacizumab sales reaching $2 billion in the U.S. in 2023, this (...)
Site référencé: The Economic Times
The Economic Times
Reliance Industries to announce Q4 earnings, dividend, and fundraising plan on April 25
20/04/2025
BHEL posts 19% revenue growth to Rs 27,350 cr in FY25, hits record order inflows
20/04/2025
HDFC Bank declares Rs 22 dividend for FY25, fixes June 27 as record date
19/04/2025
ICICI Bank Q4 Results : Net profit surges 18% YoY, NII advances 11%
19/04/2025
HDFC Bank Q4 results : Net profit jumps 6.7% YoY ; NII rises 10%
19/04/2025
Smallcap stocks deliver weekly gains of up to 30% in 3-day truncated week
19/04/2025
